title: Elevated serum heart-type fatty acid-binding protein in the convalescent stage predicts long-term outcome in patients surviving acute myocardial infarction.
abstract: BACKGROUND
  Little is known about the prognostic significance of elevated serum heart-type fatty acid-binding protein (H-FABP) in post-acute myocardial infarction (post-AMI) patients.
  
  
  RESULTS
  A total of 1,283 post-AMI patients with available serum samples collected in the convalescent stage were studied. During a median follow-up period of 1,785 days, 176 patients (14%) had adverse events (all-cause mortality, n=81; non-fatal MI, n=44; readmission for heart failure [HF], n=51). Patients were divided into 2 groups according to a serum H-FABP level of 6.08ng/ml, which was determined to be the optimal cut-off for discriminating all-cause mortality based on the maximum value of the area under the receiver operating characteristic curve. Patients with elevated H-FABP (>6.08ng/ml, n=224) had a significantly higher incidence of death (18.3% vs. 3.8%, P<0.001) and readmission for HF (10.3% vs. 2.6%, P<0.001), but not of non-fatal MI (4.5% vs. 3.2%, P=0.187), compared to those with H-FABP <6.08ng/ml. Multivariate Cox regression analysis indicated that elevated serum H-FABP was associated with an increased risk of mortality (hazard ratio [HR], 1.91; 95% confidence interval [CI]: 1.03-3.51, P=0.039) and readmission for HF (HR, 2.49; 95% CI: 1.15-5.39, P=0.020).
  
  
  CONCLUSIONS
  Elevated serum H-FABP during the convalescent stage of AMI predicted long-term mortality and readmission for HF after survival discharge in the post-AMI patients.
authors.affiliation: Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Japan.
authors.forename: Sen
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Daisaku
authors.initials: D
authors.lastname: Nakatani
authors.forename: Yasuhiko
authors.initials: Y
authors.lastname: Sakata
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Suna
authors.forename: Masahiko
authors.initials: M
authors.lastname: Shimizu
authors.forename: Masaya
authors.initials: M
authors.lastname: Usami
authors.forename: Masahiko
authors.initials: M
authors.lastname: Hara
authors.forename: Satoru
authors.initials: S
authors.lastname: Sumitsuji
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Nanto
authors.forename: Tatsuya
authors.initials: T
authors.lastname: Sasaki
authors.forename: Toshimitsu
authors.initials: T
authors.lastname: Hamasaki
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Sato
authors.forename: Masatsugu
authors.initials: M
authors.lastname: Hori
authors.forename: Issei
authors.initials: I
authors.lastname: Komuro
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D003289:Convalescence; D018572:Disease-Free Survival; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins / Q000097:blood*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000097:blood / Q000401:mortality / Q000628:therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000097:blood* / Q000150:complications / Q000401:mortality* / Q000628:therapy; D010359:Patient Readmission; D011237:Predictive Value of Tests; D011446:Prospective Studies; D015996:Survival Rate
chemical_list: C493408:FABP3 protein, human; D000074026:Fatty Acid Binding Protein 3; D050556:Fatty Acid-Binding Proteins